Clinical trials: Intermediate Risk Prostate Cancer
Prostate Cancer
A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone
This study investigates neoadjuvant TAK-700 orteronel for 6 months prior to prostatectomy. The three year biochemical free survival is the primary endpoint.
- Trial name
- NEPTUNE (NCT03211052)
- Testing
- TAK-700 and LHRH agonist, prostatectomy
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Centre of Experimental Medicine
Prostate Cancer
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with…
- Trial name
- NCT07548164
- Testing
- NanoKnife System, Stereotactic Body Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 224 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II
High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer
This phase II trial studies how well high-intensity focused ultrasound works in treating participants with intermediate and high-risk prostate cancer.
- Conditions
- Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III
- Trial name
- NCT03514927
- Testing
- Contrast-Enhanced Ultrasound, High-Intensity Focused Ultrasound, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Prostate Cancer
Cost-utility of Focal HIFU vs Prostatectomy
Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer
- Trial name
- EMERHIT (NCT05710861)
- Testing
- F-HIFU, Radical Prostatectomy
- Where
- 20 sites in France, Guadeloupe
- Volunteers
- 346 people
- Sponsor
- University Hospital, Bordeaux
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer
Patients with localised prostate cancer can be treated by radical prostatectomy (prostate gland removal surgery) or radiotherapy.
- Trial name
- CaNCaP02 (NCT02064608)
- Testing
- AZD2014
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Prostate Cancer
Intensity Modulated Versus Interstitial - Radiation Therapy
Purpose: The purpose of this trial is to compare two different treatment options for patients with low risk and low-tier intermediate risk prostate cancer.
- Trial name
- NCT00407875
- Testing
- Intensity Modulated External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Low and Intermediate Risk Prostate Cancer
MRI Guided Focal Laser Ablation of Prostate Cancer
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate.
- Trial name
- MRgFLA (NCT03650595)
- Testing
- The TRANBERGCLS|Thermal Therapy
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
PROSTATE CANCER
Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer
The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma…
- Trial name
- PROSINT (NCT02570919)
- Testing
- IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Fundacao Champalimaud
Prostate Cancer
Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer
This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can significantly postpone or eliminate the need of patients with organ confined intermediate risk prostate cancer to undergo a definitive treatment…
- Trial name
- NCT02968784
- Testing
- ExAblate MRgFUS
- Where
- 4 sites in Canada, China and 1 more
- Volunteers
- 53 people
- Sponsor
- InSightec
Prostate Adenocarcinoma, Radiation Toxicity
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
Hypo-Combi Trial: A Prospective Phase I/II Study of Combined Hypofractionated External Beam Radiation Therapy (EBRT) plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) for Intermediate/High Risk Prostate Cancer
- Trial name
- Hypo-Combi (NCT05003752)
- Testing
- External beam radiation therapy, High-dose-rate brachytherapy, Goserelin 10.8 mg
- Where
- Cyprus
- Volunteers
- 40 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
Proton Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT01045226
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer
Active Surveillance (AS) is a treatment option in patients with favorable risk prostate cancer. According to the current guidelines patients are monitored by prostate specific antigen (PSA) testing (every 3 months) and regular…
- Trial name
- PROMM-AS (NCT03979573)
- Testing
- Multiparametric MRI, Radiomics, MR-guided Biopsy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer.
- Trial name
- NCT05826470
- Testing
- TRANBERG®|Thermal Therapy System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Genesis Research LLC
Prostate Cancer
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
This is a research study to test an investigational drug (Not FDA approved), Apalutamide given in combination with Leuprolide acetate (FDA approved) in men diagnosed with high-risk prostate cancer who have already selected to…
- Trial name
- NCT02770391
- Testing
- Leuprolide acetate, Apalutamide, Radical prostatectomy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center
Localized Prostate Carcinoma, Castration-Naive Prostate Cancer
Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer
Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound.
- Conditions
- Localized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer
- Trial name
- NeoADT-TULSA (NCT05917860)
- Testing
- Degarelix, MRI-guided transurethral ultrasound ablation (TULSA)
- Where
- Finland
- Volunteers
- 15 people
- Sponsor
- Turku University Hospital
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer
Stereotactic ablative body radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), is a specialized form of radiotherapy used to treat prostate cancer with five treatments over two weeks, compared with a conventional…
- Trial name
- NCT03159676
- Testing
- Proton beam
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Prostate Cancer
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
Primary Objective: To assess the possible improvement in prostate specific antigen (PSA) outcome of short course androgen suppression therapy in conjunction with dose-escalation intensity modulated radiation therapy (IMRT), 3D…
- Trial name
- NCT00388804
- Testing
- Radiation Therapy, Bicalutamide, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Stereotactic body radiation therapy (SBRT) is a very precise form of radiation therapy that allows the physician to deliver more radiation dose in a single session.
- Trial name
- NCT03056638
- Testing
- Degarelix, stereotactic body radiosurgery (SBRT)
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center